INmune Bio Inc
NASDAQ:INMB

Watchlist Manager
INmune Bio Inc Logo
INmune Bio Inc
NASDAQ:INMB
Watchlist
Price: 1.52 USD 2.01%
Market Cap: 40.4m USD

INmune Bio Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

INmune Bio Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
INmune Bio Inc
NASDAQ:INMB
Net Income (Common)
-$49.9m
CAGR 3-Years
-17%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

INmune Bio Inc
Glance View

Market Cap
40.4m USD
Industry
Biotechnology

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2019-02-04. The firm is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). The company has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer's and treatment-resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.

INMB Intrinsic Value
4.77 USD
Undervaluation 68%
Intrinsic Value
Price

See Also

What is INmune Bio Inc's Net Income (Common)?
Net Income (Common)
-49.9m USD

Based on the financial report for Sep 30, 2025, INmune Bio Inc's Net Income (Common) amounts to -49.9m USD.

What is INmune Bio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-35%

Over the last year, the Net Income (Common) growth was -21%. The average annual Net Income (Common) growth rates for INmune Bio Inc have been -17% over the past three years , -35% over the past five years .

Back to Top